Table 3.

Multivariable binary logistic regression analysis for hospitalization and mortality.

Outcome	Independent Factors	Odds Ratio	95% C.I. for Odds Ratio	p-Value
Hospitalization
	Age	1.065	1.050–1.081	<0.001
	Male sex	1.639	1.231–2.184	0.001
	DMT			<0.001
	ALEMTUZUMAB *	-	-	-
	AZATHIOPRINE *	0.248	0.075–0.819	0.022
	CLADRIBINE *	0.442	0.165–1.186	0.105
	DMF *	0.423	0.266–0.673	<0.001
	FINGOLIMOD *	0.589	0.384–0.904	0.016
	GLATIRAMER ACETATE *	0.388	0.225–0.667	0.001
	INTERFERON *	0.231	0.139–0.383	<0.001
	NATALIZUMAB *	0.078	0.010–0.588	0.013
	OCRELIZUMAB *	1.471	0.675–3.207	0.332
	RITUXIMAB *	1.507	0.366–6.200	0.570
	TERIFLUNOMIDE *	0.391	0.215–0.711	0.002
	Number of comorbidities			0.007
	1 **	1.437	0.996–2.072	0.052
	2 **	0.790	0.444–1.404	0.422
	3 **	2.569	1.402–4.707	0.002
	4+ **	0.980	0.360–2.673	0.969
	Partially or fully vaccinated ***	0.380	0.281–0.513	<0.001
Death due to COVID-19
	Age	1.110	1.061–1.162	<0.001
	Male sex	2.103	0.909–4.866	0.082
	DMT			0.944
	ALEMTUZUMAB *	-	-	-
	AZATHIOPRINE *	-	-	-
	CLADRIBINE *	2.026	0.226–18.155	0.528
	DMF *	0.648	0.158–2.657	0.547
	FINGOLIMOD *	0.964	0.294–3.165	0.952
	GLATIRAMER ACETATE *	0.235	0.028–1.984	0.183
	INTERFERON *	0.302	0.062–1.469	0.138
	NATALIZUMAB *	-	-	-
	OCRELIZUMAB *	-	-	-
	RITUXIMAB *	-	-	-
	TERIFLUNOMIDE *	0.684	0.138–3.391	0.642
	Number of comorbidities			0.255
	1 **	2.684	0.965–7.469	0.059
	2 **	0.705	0.124–4.024	0.695
	3 **	1.996	0.479–8.309	0.342
	4+ **	2.304	0.370–14.358	0.371
	Partially or fully vaccinated ***	0.488	0.201–1.185	0.113

* Compared to the None DMT category. ** Compared to the zero number of comorbidities category. *** Compared to the unvaccinated category.